Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Schoenfeld

Radiation Oncology Boston, MA Medical Doctor

NPI 1295994978 CMS profile 769902

450 Brookline Ave # Dal2-57, Department Of Radiation Oncology, Boston, MA 02215

Open in the dashboard

General payments

$53,313

25 records reported · program years 2019–2025

Research payments

$747

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,610,632 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jonathan Schoenfeld of Boston, MA is reported in the CMS Open Payments database as having received $53,313 across 25 general payments and $747 in research payments paid to them. Separately, studies naming them as principal investigator received $1,610,632 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $271 4
2024 General $24,838 9
2024 Research $415 2
2023 General $5,877 6
2022 General $19,357 5
2021 General $2,970 1
2019 Research $331 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Schoenfeld
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Jonathan Schoenfeld were reported at $271. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Jonathan Schoenfeld Radiation Oncology median Middle half National median
2019 $0 $138 $48–$462 $163
2020 $0 $79 $26–$262 $114
2021 $2,970 $119 $37–$358 $132
2022 $19,357 $139 $43–$424 $149
2023 $5,877 $167 $57–$473 $160
2024 $24,838 $168 $56–$541 $164
2025 $271 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck KGaA $27,107 6 payments
  2. EMD Serono, Inc. $20,636 12 payments
  3. Genentech, Inc. $2,970 1 payment
  4. EMD Serono Research & Development Institute, Inc. $2,070 1 payment
  5. Regeneron Pharmaceuticals, Inc. $259 1 payment
  6. Lantheus Medical Imaging, Inc. $239 3 payments
  7. Biotronik Inc. $33 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $38,988 9 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,120 2 payments
  3. Food and Beverage $1,205 14 payments
Products named General payments · program years 2019–2025
  1. LIBTAYO $259 1 payment
  2. BIOMONITOR $33 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $747 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

20

Median for Radiation Oncology: 65

Drug cost

$300

Median for Radiation Oncology: $978

Branded share of claims

0%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mometasone Furoate Generic 20 $300

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$66,419

Medicare's payments for the services billed

Medicare patients

145

Average age 73

Services billed

954

51 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 40%
Cancer 38%
Ischemic heart disease 33%
Atrial fibrillation 23%
Depression 23%
Chronic kidney disease 22%
Diabetes 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record